The Glanzmann Thrombasthenia Registry: safety of platelet therapy in patients with Glanzmann thrombasthenia and changes in alloimmunization status

Affiliations

• ¹ Departments of Medicine, Pediatrics and Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Medical Centre, Calgary, Alberta. mcpoon@ucalgary.ca.
• ² Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles, Hôpital Bicêtre, AP-HP, and HITh, UMR_S1176, INSERM. Université Paris Saclay, Le Kremlin-Bicêtre.
• ³ Biostatistics and Programming GD GBS, Novo Nordisk Service Centre India Private Ltd, Whitefield, Bangalore.
• ⁴ Institute for Laboratory Medicine, Blood Coagulation and Transfusion Medicine (LBT), Düsseldorf, Germany; Department of Hemostasis, Hemotherapy and Transfusion Medicine, Heinrich Heine University Medical Centre, Düsseldorf.
• ⁵ Department of Clinical Medicine and Surgery, Regional Reference Center for Coagulation Disorders, Federico II University, Naples.